Ligand to Participate in May Investor Conferences

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) has announced its senior management team's participation in three upcoming investor conferences in May 2025:

• H.C. Wainwright Royalty Company Conference (Virtual) - Fireside chat on May 13 at 3:30 p.m. ET
• RBC Capital Markets Global Healthcare Conference (New York) - Fireside chat on May 20 at 2:05 p.m. ET
• Craig-Hallum Institutional Investor Conference (Minneapolis) - One-on-one meetings on May 28

Management will be available for one-on-one meetings with investors during all conferences. Interested investors should contact their respective conference representatives to arrange meetings.

News Market Reaction

-0.65%

1 alert

-0.65% News Effect

On the day this news was published, LGND declined 0.65%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:

• H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.
  
  
• RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available for one-on-one meetings.
  
  
• Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 28, 2025.
  

Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their H.C. Wainwright, RBC, or Craig-Hallum representative.

About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

What investor conferences will LGND attend in May 2025?

Ligand will attend three conferences: H.C. Wainwright Royalty Company Conference (Virtual) on May 13, RBC Capital Markets Global Healthcare Conference in New York on May 20, and Craig-Hallum Institutional Investor Conference in Minneapolis on May 28, 2025.

When is Ligand's fireside chat at the RBC Capital Markets Healthcare Conference?

Ligand's fireside chat at the RBC Capital Markets Global Healthcare Conference is scheduled for May 20, 2025, at 2:05 p.m. ET in New York.

How can investors arrange one-on-one meetings with LGND management?

Investors interested in one-on-one meetings should contact their H.C. Wainwright, RBC, or Craig-Hallum representative to arrange meetings during the respective conferences.

Which of LGND's May 2025 investor conferences will be virtual?

The H.C. Wainwright Royalty Company Conference on May 13, 2025, will be held virtually.